secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001628280-24-006346
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotech Q4/FY2023 net loss $116M/$615M; GSK flu pact ended; cash $1.63B
---------------------------------------------------------------------------

- Q4 net loss $116.0M ($0.86 loss per share); FY2023 net loss $615.1M ($4.59 loss per share).
- Q4 revenue $16.8M (down 66% YoY); FY revenue $86.2M (down 95% YoY) on lower sotrovimab sales.
- Cash, cash equivalents and investments $1.63B as of Dec 31, 2023, down $108M in Q4.
- GSK influenza collaboration terminated; Vir retains sole rights to VIR-2482, VIR-2981 and pays low single-digit royalties.
- CMO Phil Pang steps down March 31, 2024; SOLSTICE hepatitis delta trial enrollment ahead of schedule with initial data expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828024006346/0001628280-24-006346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828024006346/vir-20240221.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-006346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer